argenx
- Country
- 🇧🇪Belgium
- Ownership
- -
- Established
- 2008-01-01
- Employees
- -
- Market Cap
- $31.2B
- Website
- https://www.argenx.com/
A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)
- Conditions
- Antibody-mediated Rejection
- Interventions
- Combination Product: Efgartigimod PH20 SC - prefilled syringeOther: Placebo PH20 SC - prefilled syringe
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- argenx
- Target Recruit Count
- 30
- Registration Number
- NCT06503731
- Locations
- 🇺🇸
University of Alabama at Birmingham (UAB) Hospital, Birmingham, Alabama, United States
🇨🇦London Health Sciences Centre, London, Canada
🇨🇿Institut klinicke a experimentalni mediciny (IKEM), Praha, Czech Republic
A Safety and Efficacy Study of ARGX-119 in Adult Patients with Amyotrophic Lateral Sclerosis (ALS)
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Other: Placebo
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- argenx
- Target Recruit Count
- 60
- Registration Number
- NCT06441682
- Locations
- 🇫🇷
Hôpital La Pitié Salpêtrière, Paris, France
🇸🇪Akademiskt specialistcentrum Karolinska Institutet, Stockholm, Sweden
🇫🇷CHU Bretonneau, Tours, France
A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants with DOK7-Congenital Myasthenic Syndromes (CMS)
- Conditions
- Congenital Myasthenic Syndrome
- Interventions
- Other: Placebo
- First Posted Date
- 2024-05-31
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- argenx
- Target Recruit Count
- 16
- Registration Number
- NCT06436742
- Locations
- 🇺🇸
UC Davis Medical Center, Sacramento, California, United States
🇺🇸Ann and Robert H Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States
🇨🇦Ottawa Hospital Research Institute - Civic Campus, Ottawa, Canada
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age with Generalized Myasthenia Gravis
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Biological: Efgartigimod PH20 SC
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- argenx
- Target Recruit Count
- 12
- Registration Number
- NCT06392386
- Locations
- 🇳🇱
Leiden University Medical Center, Leiden, Netherlands
🇺🇸Neurology Rare Disease Center, Denton, Texas, United States
🇧🇪UZ Gent, Gent, Belgium
A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease
- Conditions
- Thyroid Eye Disease
- Interventions
- Combination Product: Efgartigimod PH20 SCOther: Placebo PH20 SC
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- argenx
- Target Recruit Count
- 108
- Registration Number
- NCT06307613
- Locations
- 🇺🇸
University Of Southern California - Keck School Of Medicine, Los Angeles, California, United States
🇺🇸Wilmer Eye Institute, Baltimore, Maryland, United States
🇩🇪Universitaetsklinikum Muenster, Muenster, Germany
A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.
- Conditions
- Thyroid Eye Disease
- Interventions
- Combination Product: Efgartigimod PH20 SCOther: Placebo PH20 SC
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2025-05-05
- Lead Sponsor
- argenx
- Target Recruit Count
- 108
- Registration Number
- NCT06307626
- Locations
- 🇯🇵
Kozawa Eye Hospital and Diabetes Center, Mito, Japan
🇩🇪Universitaetsaugenklinik Ulm, Ulm, Germany
🇮🇹Ospedale Cisanello, Pisa, Italy
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy And/or Breastfeeding.
- Conditions
- Myasthenia GravisCIDP - Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- Biological: Efgartigimod
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- argenx
- Target Recruit Count
- 279
- Registration Number
- NCT06299748
- Locations
- 🇺🇸
United BioSource LLC, Morgantown, West Virginia, United States
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- argenx
- Target Recruit Count
- 680
- Registration Number
- NCT06298565
- Locations
- 🇺🇸
SFM Clinical Research, LLC, Boca Raton, Florida, United States
🇺🇸Norton Neuroscience Institute, Louisville, Kentucky, United States
🇺🇸National Neuromuscular Research Institute, Austin, Texas, United States
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Biological: Efgartigimod IVOther: Placebo IV
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- argenx
- Target Recruit Count
- 110
- Registration Number
- NCT06298552
- Locations
- 🇨🇿
Fakultni nemocnice Brno, Brno, Czech Republic
🇺🇸HonorHealth Neurology - Bob Bove Neuroscience Institute, Scottsdale, Arizona, United States
🇺🇸Loma Linda University Health, Fresno, California, United States
A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis
- Conditions
- MyositisDermatomyositis
- Interventions
- Biological: Empasiprubart IVOther: Placebo IV
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2025-05-05
- Lead Sponsor
- argenx
- Target Recruit Count
- 42
- Registration Number
- NCT06284954
- Locations
- 🇬🇷
Andreas Syggros Hospital of Skin and Venereal Diseases - University Dermatology and Venereology, Athens, Greece
🇲🇩Institute of Cardiology, Chisinau, Moldova, Republic of
🇵🇱Nova Reuma Domyslawska i Rusilowicz- Spolka Partnerska Lekarza Reumatologa i Fizjoterapeuty, Bialystok, Poland